BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ogawa H, An Y, Nishi H, Fukuda S, Ishigami K, Ikeda S, Doi K, Ide Y, Hamatani Y, Fujino A, Ishii M, Iguchi M, Masunaga N, Esato M, Tsuji H, Wada H, Hasegawa K, Abe M, Tsukahara T, Lip GYH, Akao M. Characteristics and clinical outcomes in atrial fibrillation patients classified using cluster analysis: the Fushimi AF Registry. Europace 2021:euab079. [PMID: 33930126 DOI: 10.1093/europace/euab079] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Proietti M, Vitolo M, Harrison SL, Lane DA, Fauchier L, Marin F, Nabauer M, Potpara TS, Dan GA, Boriani G, Lip GYH; ESC-EHRA EORP-AF Long-Term General Registry Investigators. Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. BMC Med 2021;19:256. [PMID: 34666757 DOI: 10.1186/s12916-021-02120-3] [Reference Citation Analysis]
2 Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, Guo Y, Sriratanasathavorn C, Oh S, Okumura K, Lip GYH. 2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. J Arrhythm 2021;37:1389-426. [PMID: 34887945 DOI: 10.1002/joa3.12652] [Reference Citation Analysis]
3 Yao Y, Guo Y, Lip GYH; mAF-App II Trial investigators. The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity: The mAFA-II Randomized Clinical Trial. JAMA Netw Open 2021;4:e2140071. [PMID: 34932104 DOI: 10.1001/jamanetworkopen.2021.40071] [Reference Citation Analysis]